The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BMMNC) on all causemortality in acute myocardial infarction - BAMI

Queen Mary University London0 个研究点目标入组 3,000 人开始时间: 2015年11月19日最近更新: 2019年12月10日

适应症

试验速览

暂无简介。

•1. Signed and dated informed consent
•2. Men and women of any ethnic origin aged = 18 years
•3. Patients with acute STelevation (including new LBBB) myocardial infarction as defined by the universal definition of AMI.
•4. Successful acute reperfusion therapy (residual stenosis visually <50% and TIMI flow =2) within 24 hours of symptom onset or thrombolysis within 12 hours of symptom onset followed by successful percutaneous coronary intervention (PCI) within 24 hours after thrombolysis
•5. Left ventricular ejection fraction = 45% with significant regional wall motion abnormality assessed by quantitative echocardiography (central, independent core lab analysis) 3 to 6 days after reperfusion therapy
•6. Open coronary artery suitable for cell infusion supplying the target area of abnormal wall motion
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1800
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 1200

•1. Participation in another clinical trial within 30 days prior to randomisation
•2. Previously received stem/progenitor cell therapy
•3. Pregnant or nursing women
•4. Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study or to follow the
•5. Necessity to revascularise additional vessels, outside the target coronary artery at the time of BMMNC infusion (additional revascularisations after primary PCI and before BMMNC cell infusion are allowed), unless clinically indicated and according to latest guidelines. This decision should be madfe at the time of the index procedure and explicitly stated at the time.
•6. Cardiogenic shock requiring mechanical support
•7. Platelet count <100,000/µl, or hemoglobin <8.5 g/dl
•8. Impaired renal function, i.e. serum creatinine >2.5 mg/dl
•9. Persistent fever or diarrhea not responsive to treatment within 4 weeks prior screening
•10. Clinically significant bleeding within 3 months prior screening
•11. Uncontrolled hypertension (systolic >180 mmHg and diastolic >120 mmHg)
•12. Life expectancy of less than 2 years from any noncardiac cause or neoplastic disease

发起方